The Role of the FCRL5 Protein in the Pathophysiology of Multiple Sclerosis and Response to Treatment

Sponsor
Université Catholique de Louvain
Study ID
NCT07788573
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • A blood test every 6 months for MS patients. — OTHER
    A blood test every 6 months for MS patients : Day1, Month 6, Month 12 and Month 24
  • A single blood draw for the healthy volunteer — OTHER
    A single blood draw for the healthy volunteer
  • A single blood draw for the group of volunteers with Sjögren's syndrome — OTHER
    A single blood draw for the group of volunteers with Sjögren's syndrome

Study Details

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system (CNS) and the leading non-traumatic cause of neurological disability in young adults. Historically considered a T-cell-mediated disease, the paradigm for MS has shifted thanks to the efficacy of therapies targeting B cells. The investigators recently identified FCRL5 as a B-cell-specific biomarker that is significantly elevated in the cerebrospinal fluid (CSF) of patients with relapsing-remitting MS and is independently associated with an increased risk of developing new MRI lesions within two years of diagnosis (ref. Deltombe et al., PMID: 41004694). This project aims to further explore FCRL5 as a prognostic biomarker, study the role of FCRL5-expressing B cells in MS pathogenesis and the effects of disease-modifying therapies on these subsets.

Key Dates

First listed
Aug 26, 2026
Start date
Aug 31, 2026
Status verified
Aug 2026
Primary completion
Dec 31, 2029
Completion
Dec 31, 2029

Study Design

Enrollment
90 participants (estimated)

Arms

  • Arm: A group of patients with MS
  • Arm: A group of healthy volunteers
  • Arm: A group of volunteers with Sjögren's syndrome

Primary Outcome Measure

Characterization of the phenotype of peripheral CD19⁺CD11c⁺FCRL5⁺ B lymphocytes in patients with MS [ Time Frame: Throughout the entire study, approximately during 40 months ]

Find similar trials

Nationwide
Multiple sclerosis trialsNeurology trialsBrain disorders trialsAutoimmune disease trials

Related Studies